| Котировки и графики в реальном времени | Новости | Фундаментальные показатели | Компания | Добавить | |
|---|---|---|---|---|---|
| Котировки и график | Ход торгов | Новости | Оценки | Календарь | В портфель |
| Последние сделки | Прогнозы аналитиков | Дивиденды | Профиль | В список наблюдения | |
| Биржи | Целевые цены | Баланс | |||
| Архив торгов | |||||
Pfizer Inc. - Профиль
Pfizer Inc. (Pfizer) – глобальная биофармацевтическая компания. Изобретатель и производителем всемирно известного препарата «Виагра». В 2012 году продажи компании упали на 8% до $57,9 млрд, что было связано с появлением дженериков для ряда ее препаратов, в том числе препарата для снижения уровня холестерина в крови «Липитор». Это одно из наиболее продаваемых лекарств в США и мире. В 2012 году продажи «Липитора» компании Pfizer упали на 60%. Выручка от реализации «Виагры» (6-е место среди наиболее продаваемых препаратов компании) выросла на 4%, до $2,1 млрд.
Акционеры
| Название | Доля (%) |
|---|---|
| The Vanguard Group, Inc. | 7,96 |
| SSgA Funds Management, Inc. | 5,36 |
| BlackRock Fund Advisors | 4,82 |
| Capital Research & Management Co. (World Investors) | 2,67 |
| T. Rowe Price Associates, Inc. (Investment Management) | 1,93 |
| Geode Capital Management LLC | 1,51 |
| Northern Trust Investments, Inc.(Investment Management) | 1,38 |
| Wellington Management Co. LLP | 1,36 |
| JPMorgan Investment Management, Inc. | 1,33 |
| State Farm Investment Management Corp. | 1,08 |
| Norges Bank Investment Management | 1,04 |
| Massachusetts Financial Services Co. | 1,02 |
| Dimensional Fund Advisors LP | 0,87 |
| BlackRock Investment Management (UK) Ltd. | 0,83 |
| Fisher Asset Management LLC | 0,80 |
Адрес
| 235 East 42nd Street, 10017-5755 New York | |
| а/я: | |
| Телефон: | 12127332323 |
| Факс: | |
| Вэб: | http://www.pfizer.com |
Менеджмент
| Rady A. Johnson, CPA Chief Compliance & Risk Officer, Executive VP |
| Alexander Roderick MacKenzie, PhD Chief Development Officer & Executive VP |
| Frank A. D'Amelio, MBA Chief Financial Officer & EVP-Business Operations |
| Dawn Rogers Chief Human Resources Officer & EVP |
| Freda C. Lewis-Hall, MD Chief Patient Officer & Executive Vice President |
| Mikael Dolsten MD, PhD Chief Scientific Officer |
| Lidia L. Fonseca, MBA Chief Technology Officer & EVP |
| Scott Gottlieb, MD Director |
| Albert Bourla, PhD Director, Chief Executive & Operating Officer |
| Laurie J. Olson, MBA EVP-Strategy, Portfolio & Commercial Operations |
| Ian C. Read Executive Chairman |
| Margi McLoughlin, PhD Executive Director-World Wide Business Development |
| Kirsten Lund Jurgensen, PhD Executive Vice President |
| Michael Goettler Executive Vice President |
| Douglas M. Lankler Executive Vice President & General Counsel |
| Sally Susman Executive Vice President-Corporate Affairs |
| James Marshall Kilts, MBA Independent Director |
| Ronald E. Blaylock, MBA Independent Director |
| W. Don Cornwell, MBA Independent Director |
| Dan R. Littman MD, PhD Independent Director |
| Joseph J. Echevarria Independent Director |
| James C. Smith Independent Director |
| Helen H. Hobbs MD, PhD Independent Director |
| Suzanne Nora Johnson Independent Director |
| Ryan Crowe Investor Relations Officer |
| Denise Bruns Late-Phase Development Group Leader |
| Shantanu Narayen, MBA Lead Independent Director |
| Neha Wadhwa Media Contact |
| Thomas Biegi Media Contact |
| Joan Campion Media Contact |
| Angela Hwang, MBA President-Pfizer Essential Health |
| John D. Young President-Pfizer Innovative Health |
| Andy Schmeltz President-US Oncology Business Unit |
| Mark Swindell President-Vaccines |
| Margaret M. Madden Secretary, Chief Governance Counsel & Senior VP |
| Mark White Senior Director & Group Leader-Pain Therapeutics |
| Tamas Koncz Senior Medical Director |
| Loretta V. Cangialosi Senior Vice President & Controller |
| John E. Sorrentino VP & COO-Vaccine Research & Development |
| John DeYoung Vice President-Worldwide Business Development |
| Monika A. Vnuk, MD Vice President-Worldwide Business Development |